Vista Pharma breached the 5% lower circuit at Rs.32.75, the moment is opened up for trading.

Once again, blame it on the US FDA which issued a warning letter to the company’s facility at Telangana.

The observation by the FDA happened between 19th to 23rd Sept and it has found significant violations of current good manufacturing practice regulations for finished drugs.

The observation includes failure to clean, maintain equipment & utensils at appropriate intervals. The FDA stated that the company also failed to establish procedures to assure drug strength, identity & quality.